Celldex Therapeutics Inc. (CLDX): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celldex Therapeutics ( CLDX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.3%. By the end of trading, Celldex Therapeutics fell $0.55 (-2.0%) to $27.45 on light volume. Throughout the day, 1,608,065 shares of Celldex Therapeutics exchanged hands as compared to its average daily volume of 2,195,500 shares. The stock ranged in price between $26.96-$27.86 after having opened the day at $27.47 as compared to the previous trading day's close of $28.00. Other companies within the Health Care sector that declined today were: Durect Corporation ( DRRX), down 20.5%, Dehaier Medical Systems ( DHRM), down 17.0%, Liberator Medical Holdings ( LBMH), down 11.6% and Medicines ( MDCO), down 11.5%.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Celldex Therapeutics has a market cap of $2.1 billion and is part of the drugs industry. Shares are up 15.7% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Retrophin ( RTRX), up 49.8%, Conatus Pharmaceuticals ( CNAT), up 19.2%, Cardiome Pharma Corporation ( CRME), up 16.5% and Pacira Pharmaceuticals ( PCRX), up 13.3% , were all gainers within the health care sector with Allergan ( AGN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists